Abstract
Introduction: Preliminary data indicate agomelatine as a promising molecule for both acute and long-term treatment of generalised anxiety disorder (GAD). Areas covered: The present review illustrates the pharmacokinetic properties of agomelatine and their implications for the management of GAD patients. A search of the main database sources (Medline, Isi Web of Knowledge and Medscape) was performed in order to obtain a complete and balanced evaluation of agomelatine pharmacokinetics for the treatment of GAD. The word 'agomelatine' was associated with 'pharmacokinetics', 'GAD', 'anxiety' and 'tolerability'. No restriction criteria were established in relation to methodology or year of publication. Only English-language articles were included. Expert opinion: Short half-life and 1-day administration make agomelatine an interesting molecule for GAD treatment. However, potential interactions with a number of compounds necessitate caution when prescribing and using agomelatine in patients with psychiatric (e.g., alcohol abuse) or medical comorbidities. Further data are necessary to define a precise risk/benefit ratio in special populations such as elderly patients suffering from GAD.
| Original language | English |
|---|---|
| Pages (from-to) | 885-892 |
| Number of pages | 8 |
| Journal | Expert Opinion on Drug Metabolism and Toxicology |
| Volume | 10 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Agomelatine
- Generalised anxiety disorder
- Pharmacokinetics
ASJC Scopus subject areas
- Toxicology
- Pharmacology
- Medicine(all)
Cite this
Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder. / Buoli, Massimiliano; Mauri, Massimo Carlo; Altamura, Alfredo Carlo.
In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, No. 6, 2014, p. 885-892.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder
AU - Buoli, Massimiliano
AU - Mauri, Massimo Carlo
AU - Altamura, Alfredo Carlo
PY - 2014
Y1 - 2014
N2 - Introduction: Preliminary data indicate agomelatine as a promising molecule for both acute and long-term treatment of generalised anxiety disorder (GAD). Areas covered: The present review illustrates the pharmacokinetic properties of agomelatine and their implications for the management of GAD patients. A search of the main database sources (Medline, Isi Web of Knowledge and Medscape) was performed in order to obtain a complete and balanced evaluation of agomelatine pharmacokinetics for the treatment of GAD. The word 'agomelatine' was associated with 'pharmacokinetics', 'GAD', 'anxiety' and 'tolerability'. No restriction criteria were established in relation to methodology or year of publication. Only English-language articles were included. Expert opinion: Short half-life and 1-day administration make agomelatine an interesting molecule for GAD treatment. However, potential interactions with a number of compounds necessitate caution when prescribing and using agomelatine in patients with psychiatric (e.g., alcohol abuse) or medical comorbidities. Further data are necessary to define a precise risk/benefit ratio in special populations such as elderly patients suffering from GAD.
AB - Introduction: Preliminary data indicate agomelatine as a promising molecule for both acute and long-term treatment of generalised anxiety disorder (GAD). Areas covered: The present review illustrates the pharmacokinetic properties of agomelatine and their implications for the management of GAD patients. A search of the main database sources (Medline, Isi Web of Knowledge and Medscape) was performed in order to obtain a complete and balanced evaluation of agomelatine pharmacokinetics for the treatment of GAD. The word 'agomelatine' was associated with 'pharmacokinetics', 'GAD', 'anxiety' and 'tolerability'. No restriction criteria were established in relation to methodology or year of publication. Only English-language articles were included. Expert opinion: Short half-life and 1-day administration make agomelatine an interesting molecule for GAD treatment. However, potential interactions with a number of compounds necessitate caution when prescribing and using agomelatine in patients with psychiatric (e.g., alcohol abuse) or medical comorbidities. Further data are necessary to define a precise risk/benefit ratio in special populations such as elderly patients suffering from GAD.
KW - Agomelatine
KW - Generalised anxiety disorder
KW - Pharmacokinetics
UR - http://www.scopus.com/inward/record.url?scp=84901052733&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901052733&partnerID=8YFLogxK
U2 - 10.1517/17425255.2014.907794
DO - 10.1517/17425255.2014.907794
M3 - Article
VL - 10
SP - 885
EP - 892
JO - Expert Opinion on Drug Metabolism and Toxicology
JF - Expert Opinion on Drug Metabolism and Toxicology
SN - 1742-5255
IS - 6
ER -